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MSKCCINTRODUCTION
Despite guidelines from the Centers for Disease
Control (CDC) [1] and European Blood and Marrow
Transplant (EBMT) center [2], most centers do not
consistently revaccinate patients following hematopoi-
etic stem cell transplantation (HCT) nor know the
efficacy of these guidelines in their patient population
[3]. The current guidelines advocate initiation of
posttransplant vaccination at 6-12 months post-HCT,
irrespective of an individual’s level of immune compe-
tence (Figure 1). Nevertheless, the kinetics of T and B
cell reconstitution following a related or unrelated
transplant (Figures 2 and 3), affected by age and the
presence or absence of graft versus host disease is vari-
able. Although vaccination of all transplant patients
using a standard time table may be a simple and less
costly intervention, proof that it is efficacious for all
vaccine types is lacking. Over the last decade improved
disease-free survival (DFS) following HCT [4-8] has
resulted in increasing numbers of HCT survivors re-
turning to school and the workplace. Whereas immu-
nization of healthy children and young adults is
considered protective because of the .90% serocon-
version rates observed (reviewed in [9]), the ability of
HCT patients to respond to childhood vaccines is
less well known (reviewed in [3]). A number of studies
have demonstrated that in the absence of revaccina-
tion, levels of preexisting antibody titers wane with
time post-HCT (reviewed in [3]). By 2 years post-
HCT, most patients will have lost protection against
tetanus [10], although approximately 50% will have
persistent titers against measles, mumps, and/or ru-
bella [11]. This unfortunately lulls physicians into
omitting measles, mumps, and rubella (MMR) revacci-
nation in patients capable of response [12], most of
whom will have lost seroprotection within 3 to 5 years
post-HCT [11]. During the last decade, outbreaks
of measles [13,14], mumps [15], pertussis [16], and
varicella [17] have occurred in the United States. The
index cases were either unimmunized individuals
[13-15] or previously immunized individuals [17] who
lost protective antibody. Breakthrough outbreaks54of varicella have occurred. These outbreaks stress
the continued vulnerability of inadequately vacci-
nated HCT patients and the need for proven vaccine
trategies.
Vaccine preventable infections, including, but not
limited to pneumococcus [18-20], influenza [21], and
varicella [22-24] remain a significant cause of morbid-
ity, rehospitalization, and mortality late after success-
ful HCT. A European survey [18] reported invasive
pneumococcal infections in 12.2/1000 alloHCT recip-
ients, 10 times the reported incidence in healthy indi-
viduals, excluding infants and the elderly. Eighteen
percent of pneumococcal infections were fatal. Chen
et al [20] evaluated the incidence of pneumonia
in 1375 patients following HCT. With a median fol-
low-up of 2 years, 25% of patients developed at least
1 episode of pneumonia after discharge home. Bacte-
rial pneumonia, of which pneumococcus was the
most frequent isolate, accounted for 22% of cases in
which a specific etiology could be identified [20]. In
a study by Machado et al [21], influenza occurred in
30 of 118 consecutive alloHCT patients. Although
yearly influenza vaccination is recommended for all
patients .6 months post-HCT, only 44% of vaccine
eligible patients were immunized. Influenza A devel-
oped in 2 of 19 vaccinated patients compared to 12
of 24 unimmunized patients (P\ .05). Varicella repre-
sents a significant cause of morbidity post-alloHCT
[22-24]. The estimated cumulative incidence of vari-
cella zoster virus (VZV) in 151 patients was 13% at
12 months, 32% at 24 months, and 38% at 28 months
[22]. In another study of 100 consecutive adults under-
going allogeneic BMT, 41 patients (41%) developed
VZ reactivation [23]. Among the 47 patients in this
study who survived more than 2 years post-HCT,
59% developed Zoster. Forty percent of patients
with VZV reactivation required admission with
a mean hospital stay of 7.2 days. Two patients devel-
oped encephalitis, and 1 died despite antiviral therapy.
Postherpetic neuralgia and peripheral neuropathy de-
veloped in 68% of patients. A retrospective analysis
of VZV infection in children demonstrated that 33 of
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(24). The 2000 CDC [1] guidelines do not recommend
the live attenuated varicella vaccine, Varivax, in any pa-
tient, including those who have never been vaccinated
or infected with varicella. Studies have shown that Var-
ivax is safe and effective in children with ALL in remis-
sion [25] and in pediatric solid organ transplant
recipients, despite their need for life-long immunosup-
pression [26]. Vaccination in these populations was not
associated with an increase in the incidence of herpes
zoster [24-26]. Administration of the live attenuated
varicella, Varilrix, was safe and effective in 15 children
vaccinated 12-23 months following HCT [27].
IMMUNOGENICITY OF VACCINES POST-HCT
Current literature on vaccine efficacy following
alloHCT has often been limited by a small number
of heterogeneous patients, use of inconsistent vaccina-
tion schedules, and lack of long-term follow-up. These
studies have shown conflicting results even between
adult and pediatric recipients of an unmodified HLA-
matched sibling BMT (reviewed in [3]). Ljungman et
al [28] demonstrated that only 42%, 36%, and 21%
of patients immunized with 1 IPV developed a 4-fold
rise in titer against serotypes 1, 2, and 3, respectively.
Following 3 IPV doses, 50% of patients responded to
all 3 serotypes [28]. This contrasts with a study by
Parkkali et al [29] in adult HLA-matched sibling
BMT recipients, in which all patients responded
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Figure 1. Summary of re-vaccination schedules recommended by
the CDC versus European Blood and Marrow Transplantation
Association following HCT.
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Figure 2. Median B Cell Recovery following T cell depleted or
T-replete Unrelated HCT.to IPV whether randomized to vaccination with IPV
at 6, 8, and 14 months (n 5 23) or at 18, 20, and
26 months (n 5 22). In our center [30], 210 of 219
recipients of an alloHCT responded to a series of
3 IPV when administered following acquisition of
minimal milestones of immune competence (CD4
.200/mL, PHA within 10% of normal). The range
of responses observed in these 3 studies (50%-100%)
may reflect in part variable levels of immune compe-
tence at the time of revaccination.
Pure polysaccharide antigens, including the 23-
valent pneumococcal vaccine Pneumovax (PPV23),
are poor immunogens in healthy infants (reviewed in
[9]) and HCT recipients [31-35], populations at risk
for severe invasive pneumococcal and H flu infections.
Guinan et al [31] demonstrated a\20% response to
PPV administered as a single dose at 24 months or in
a 2-dose regimen at 12 and 24 months post-HCT. At
our center, \25% of 156 patients responded to .3
pneumococcal serotypes following immunization
with PPV [33]. Response was poor in all age groups,
whether vaccinated early (\24 months) or later post-
HCT. In a study of 53 pediatric recipients of an autol-
ogous or allogeneic HCT, Avanzini et al [34] reported
that all children vaccinated more than 2 years after
transplantation responded to PPV, whereas responses
were observed in only 20%-30% and 50% of those
immunized with PPV at 0.5-1.0 year or 1-2 years
post-HCT, respectively. In univariate analysis, the
interval between BMT to vaccination, presence of
chronic graft-versus-host disease (cGVHD), and fe-
male sex influenced the response rate. In multivariate
analysis, only time betweenmarrow transplant and im-
munization predicted response. These data suggest
a deficiency of critical B cell and/or antigen presenting
cells necessary to respond to the T cell-independent
pneumococcal polysaccharide antigens during the first
2 years post-HCT. During the first year post-HCT,
the circulating B cells of patients following an autolo-
gous or allogeneic HLA matched T cell-depleted or
unmodified BMT express an immature phenotype
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Figure 3.Median CD41 cell count/ul following T cell depleted or
T-replete Unrelated BMT: Children Versus Adults.
56 T. Small(CD1c, CD5, CD38, CD231) similar to B cells de-
rived from cord blood and young children (39). These
B cells decline during the first 2 years of life in normal
children and the first 2 years in HLA-matched sibling
unmodified and TCDHCT [36]. Predominance of an
immature B cell population may explain the poor re-
sponse of patients following HCT to pure polysaccha-
ride vaccines such as PPV3 and the nonconjugated
meningococcal vaccine, justifying the use of the conju-
gated variant in all patients following HCT.
Immunization of healthy infants with the Hemo-
philus influenza (HIB) and pneumococcal protein
conjugate (PCV7) vaccines at 2, 4, and 6 months of
age, results in protective titers in .90%, reducing
the incidence of invasive infections in children and
adults exposed to vaccinated children [9,37]. To date,
2 studies have evaluated PCV7 in allogeneic transplant
recipients [38,39]. Moline et al [38] evaluated PCV7 in
recipients of anHLA-matched sibling BMT, including
the role of pretransplant immunization of the donor
and/or host. All patients were vaccinated at 3, 6, and
12 months post-HCT. Immunization of the donor
and host with PCV7 immediately prior to transplant
was associated with a significant rise in pneumococcal
tiers following rechallenge at 3 months compared to
donor/host pairs in which neither was vaccinated be-
fore HCT (P 5 .05). Following the third dose of
PCV7, 60% of patients in both groups demonstrated
significant pneumococcal titers. A similar study per-
formed by Storek et al [35] showed no advantage to
pre-HCT immunization of the donor and/or host
with PPV. A recent study byMeisel et al [39], evaluated
PCV7 response in 53 children\16 years of age follow-
ing a related or unrelated HCT. Of the 43 evaluable
patients, 74% responded to all 7 serotypes following
3 immunizations with PCV7 initiated 6 months post-
HCT. Comparison of response in children on or off
immunosuppressive therapy at the start of vaccination
demonstrated that 3 of 7 compared to 29 of 36 patients,
respectively, responded to the vaccine (P 5 .06).
We have analyzed the response of alloHCT pa-
tients to H flu conjugate vaccine (HIB), the 23-valent
pure polysaccharide pneumococcal vaccine (Pneumo-
vax, PPV) and/or the 7-valent conjugated pneumococ-
cal vaccine (Prevnar, PCV7) [35]. Ninety percent of
256 patients responded to HIB. Only 24% of 156 pa-
tients responded to Pneumovax. Similar to the study
of Guinan et al [34], there was no significant difference
in response in patients given Pneumovax 12-24
months or .24 months post-HCT. In contrast, 98
of 138 patients (71%) responded to a series of PCV7.
Response was observed in 90% of children (70 of 78)
compared to only 48% of adults (29 of 60) (P \
.001). There were significant differences between re-
sponders and nonresponders in terms of age at trans-
plant (P\ .001) and age at vaccination (P\ .001). In
addition, there was a marginal difference in responsebased on history of prior but inactive cGVHD status
(P5 .06). Only 1 of 8 patients who failed initial vacci-
nation with Pneumovax responded to a second vaccine.
In contrast, 25 of 35 patients who failed Pneumovax
subsequently responded to a series of the PCV7
vaccine.
In 2006, we published our analysis of the immuno-
genicity of recombinant Hepatitis B vaccine (rHBV)
and inactivated polio vaccine (IPV) in over 200 alloge-
neic transplant patients [30]. Prior to this report, there
were only a limited number of studies evaluating the
ability of HCT recipients to respond to rHBV, and
none performed in recipients of an unrelated or HLA-
mismatched related HCT and/or a T cell-depleted
(TCD) HCT from any donor type (reviewed in [9]).
In the 2000 CDC guidelines, Hepatitis B vaccination
is optional [6]. Nevertheless, revaccination against
Hep B is mandatory for reentry to school and certain
workplaces. Machado et al [40,41] reported a 100%
seroconversion rate in 5 autologous and 45 HLA-
matched related HCT recipients immunized at least
1 year after transplant. Despite this excellent initial re-
sponse, 60% of patients failed to sustain titers for more
than 1 year after HCT [41]. In our study of 267 alloge-
neic transplant recipients immunized with rHBV
following acquisition of limited minimal milestones
of immune competence, a 64% seroconversion rate
was observed [30]. Seventy-three percent of 99 chil-
dren and 59% of 168 adults responded (P 5 .02). In
multivariate analyses, response was adversely affected
by age .18 years (P \ .01) and history of prior
cGVHD (P\ .0001) but not by donor type, use of T
cell depletion, adoptive immunotherapy, or rituximab.
Of the 149 patients who were .24 months from their
last rHBV, 98 had serial titers obtained. Eighty pa-
tients remained seropositive 5 years following their
last vaccine. The greater proportion of patients with
sustained Hep B titers in our study, compared to
Machado’s study (40%), suggests qualitative and/or
quantitative differences in the circulating memory T
and/or B cells present at the time of vaccination. Vari-
able kinetics of CD271IgD1memory B cells has been
seen post-alloHCT [42]. Surrogate markers such as
these may be instrumental in determining the need
and timing of booster immunizations to maintain
durable protective titers following vaccination.
Although outbreaks of measles and mumps have
occurred within the last 2 years in the United States
[14,15], and receipt of 2 doses of MMR is required
for healthy children to return to school [43], there is
little data on the immunogenicity of this vaccine in
patients following HCT, particularly in recipients of
unrelated or cord blood transplants. Ljungren et al
[12] evaluated the MMR response of 20 seronegative
patients following a matched sibling BMT, none of
whomhad activeGVHDorwere on systemic immuno-
suppression. Following vaccination, 77% of patients
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75% to rubella. A study by King and colleagues [44]
in 22 children who received an HLA-matched sibling
transplant at a median age of 6.9 years of age showed
similar results. Following vaccination initiated at
a median of 48 months post-HCT, 68% of children
responded to all 3 immunogens, with 77%, 87%, and
91% of children responding to measles, mumps, and
rubella, respectively. We have evaluated the response
of 113 children to MMR following a related (n 5 60)
or unrelated (n 5 38) HCT. Overall, 70% of patients
developed protective titers against measles following
a single MMR, including 42 recipients of an HLA-
matched related HCT and 27 recipients of an unre-
lated HCT (P 5 NS). Despite lack of response in
30% of patients, there were no significant adverse
reactions.
New Vaccines
In the last 5 years, several vaccines have been ap-
proved by the U.S. Food and Drug Administration
(FDA) whose use in children and adults has been rec-
ommended by the Advisory Committee for Immuniza-
tion Practices (ACIP). These include the protein
conjugated meningococcal vaccine (Menactra II,
Merck, West Point, PA) [45], the quadrivalent HPV
(Types 6, 11, 16, 18) recombinant vaccine (Gardasil,
Merck) [46], and Tdap containing tetanus toxoid,
reduced diphtheria toxoid, and acellular pertussis vac-
cine adsorbed (Adacel, Sonafi Pasteur) [46]. In 2004,
over 25,000 cases of pertussis were reported in the
United States [47]. Protection afforded by these vac-
cines in healthy children needs to be extended to pedi-
atric survivors of hematopoietic stem cell transplant.
CONCLUSIONS
The data above emphasizes that, unlike immuniza-
tion in healthy individuals, vaccination post- HCT
does not ensure seroprotection, stressing the need to
document pre- and postvaccine titers to determine re-
sponse. It also suggests that immunization guidelines
based on time interval from HCT, irrespective of im-
mune competence, may not ensure adequate protec-
tion against certain vaccine preventable diseases. The
evidence-based rating system supporting the 2000
CDC guidelines for post- HCT vaccination [1] were
BII and BIII, indicating moderate to strong recom-
mendations based primarily on evidence from a limited
number of studies or the opinions of respected author-
ities based on clinical experience, descriptive studies,
or reports of expert opinions. New guidelines, based
on age at immunization, which incorporate recently
approved vaccines, are needed as are prospective trials
documenting the efficacy of these guidelines to protect
the growing numbers of transplant survivors.REFERENCES
1. Centers for Disease Control and Prevention. Guidelines for pre-
venting opportunistic infections among hematopoietic stem cell
transplant recipients: recommendations of CDC, the Infectious
Disease Society of America, and the American Society of Blood
and Marrow Transplantation. MMWR. 2000;49:1-128.
2. Ljungman P, Engelhard D, de la Camara R, et al. Vaccination of
stem cell transplant recipients: recommendations of the Infec-
tious DiseasesWorking Party of the EBMT, 2005. Bone Marrow
Transplant. 2005;35:737-746.
3. Machado CM. Reimmunization after hematopoietic stem cell
transplantation. Vaccine. 2005;4:19-228.
4. Al-Kasim FA, Thornley I, Rolland, et al. Single-centre experi-
ence with allogeneic bone marrow transplantation for acute
lymphoblastic leukaemia in childhood: similar survival after
matched-related and matched-unrelated donor transplants.
Br J Haematol. 2002;116:483-490.
5. Kernan NA, Boulad F, Small TN, et al. Improved outcome with
T-cell depleted (SBA-E-) marrow transplants from related and
unrelated donors for children with acute leukemia transplanted
in first or second remission. Blood. 2001;98:674a.
6. Alyea EP,Weller E, FisherDC, et al. Comparable outcomewith
T-cell-depleted unrelated-donor versus related-donor alloge-
neic bone marrow transplantation. Biol Blood Marrow Transplant.
2002;8:601-607.
7. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow trans-
plantation from unrelated donors for patients with chronic my-
eloid leukemia. N Eng J Med. 1998;338:962.
8. Chown SR, Marks DI, Cornish JM, et al. Unrelated donor bone
marrow transplantation in children and young adults with acute
myeloid leukaemia in remission. Br J Haematol. 1997;99:36.
9. Ada G. Vaccines and vaccinations. N Engl J Med. 2001;345:
1042-1053.
10. Ljungman P, Wiklund-Hammarsten M, Duraj V, et al.
Response to tetanus toxoid immunization after allogeneic bone
marrow transplantation. J Infect Dis. 1990;162:496-500.
11. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, et al.
Long-term immunity to measles, mumps, and rubella after allo-
geneic bone marrow transplantation. Blood. 1994;84:657-663.
12. Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of
vaccination of marrow transplant recipients with a live attenu-
ated measles, mumps, and rubella vaccine. J Infect Dis. 1989;
159:610-615.
13. Centers for Disease Control and Prevention. Multistate Investi-
gation of measles among adoptees from China—April 9, 2004.
MMWR Morb Mortal Wkly Rep. 2004;53:309-310.
14. Parker AA, StaggsW, DayanW, et al. Implications of a measles
outbreak in Indiana for sustained elimination of measles in the
United States. N Engl J Med. 2006;355:447-455.
15. MMWR. Update: multi-state outbreak of mumps—United
States, January 1–May 2. MMWR. 2006;55:559-563.
16. Greenberg DP. Pertussis in adolescents: increasing incidence
brings attention to the need for booster immunization of adoles-
cents. Pediatr Infect Dis J. 2005;24:721-728.
17. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a
day-care center despite vaccination. N Engl J Med. 2002;347:
1909-1915.
18. Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late inva-
sive pneumococcal infection following stem cell transplantation:
a EuropeanBoneMarrowTransplantation survey.Br JHaematol.
2002;117:444-450.
58 T. Small19. Socie G, Salooja N, Cohen A, et al. Non-malignant late effects
after allogeneic stem cell transplantation. Blood. 2003;101:
3373-3385.
20. Chen CS, Boeckh M, Seidel K, et al. Incidence, risk factors, and
mortality from pneumonia developing late after hematopoietic
stem cell transplantation. Bone Marrow Transplant. 2003;32:
515-522.
21. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL,
Pannuti CS.The benefit of influenza vaccination after bonemar-
row transplantation. Bone Marrow Transplant. 2005;36:897-900.
22. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA,
Grigg A. Varicella zoster infection after allogeneic bonemarrow
transplantation: incidence, risk factors and prevention with low-
dose aciclovir and ganciclovir. BoneMarrow Transplant. 2000;25:
657-664.
23. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus
infections following allogeneic bone marrow transplantation:
frequency, risk factors, and clinical outcome. Biol Blood Marrow
Transplant. 2000;6:44-49.
24. KawasakiH,Takayama J,OhiraM.Herpes zoster infection after
bone marrow transplantation inchildren. J Pediatr. 1996;128:
353-356.
25. Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella
vaccine use in immunocompromised children and adults. Pediat-
rics. 1986;78:757-762.
26. Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immu-
nogenicity of varicella-zoster virus vaccine in pediatric liver and
intestine transplant recipients.AmJTransplant. 2006;6:565-568.
27. Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella
vaccination in children after bone marrow transplantation.
Bone Marrow Transplant. 1997;20:381-383.
28. Ljungman P, Duraj V, Magnius L. Response to immunization
against polio after allogeneic marrow transplantation. Bone
Marrow Transplant. 1991;7:89-93.
29. Parkkali T, Stenvik M, Ruutu T, Hovi T, Volin L, Ruutu P.
Randomized comparison of early and late vaccination with inac-
tivated poliovirus vaccine after allogeneic BMT. Bone Marrow
Transplant. 1997;20:663-668.
30. Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of
recombinant hepatitis B vaccine (rHBV) in recipients of unre-
lated or related allogeneic hematopoietic cell transplantation
(HCT). Blood. 2006;108:2470-2475.
31. Guinan EC,Molrine DC, Antin JH, et al. Polysaccharide conju-
gate vaccine responses in bone marrow transplant patients.
Transplantation. 1994;57:677-684.
32. Pao MK, Papadopoulos EB, Kernan NA, et al. Immunogenicity
of haemophilus influenza and pneumococcal vaccines in related
and unrelated transplant recipients. Blood. 2006;108:178a.
33. Parkkali T, Kayhty H, Ruutu T, Volin L, Eskola J, Ruutu P. A
comparison of early and late vaccination with Haemophilus
influenzae type b conjugate and pneumococcal polysaccharide
vaccines after allogeneic BMT. Bone Marrow Transplant. 1996;
18:961-967.34. Avanzini MA, Carra AM, Maccario R, et al. Antibody response
to pneumococcal vaccine in children receiving bone marrow
transplantation. J Clin Immunol. 1995;15:137-144.
35. Storek J, Dawson MA, Lim LC. Efficacy of donor vaccination
before hematopoietic cell transplantation and recipient vaccina-
tion both before and early after transplantation. Bone Marrow
Transplant. 2004;33:337-346.
36. Small TN, Keever CA,Weiner-Fedus S, Heller G, O’Reilly RJ,
Flomenberg N. B cell differentiation following autologous, con-
ventional, or T-cell depleted bone marrow transplantation: a re-
capitulation of normal B cell ontogeny. Blood. 1990;76:
1647-1656.
37. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D,
Malinoski F. Post licensure evaluation of the effectiveness of 7
valent pneumococcal conjugate vaccine. Pediatr Infect Dis J.
2001;20:1105-1107.
38. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization
with pneumococcal conjugate vaccine and early protective anti-
body responses following allogeneic hematopoietic cell trans-
plantation. Blood. 2003;101:831-836.
39. Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate
vaccine provides early protective antibody responses in children
after related and unrelated allogeneic hematopoietic stem cell
transplantation. Blood. 2007;109:2322-2326.
40. Machado CM. Reimmunization after bone marrow transplanta-
tion-current recommendations and perspectives. Braz JMed Biol
Res. 2004;37:151-158.
41. Machado CM, Rocha IF, Diomede B, et al. Effectiveness
of Hepatitis B vaccination and persistence of immunity
after BMT. The Ninth International Symposium on Infections
in the Immunocompromised Host. Assisi, Italy, June 23-26,
1997.
42. Avanzini M, Locatelli F, Santos C, et al. B lymphocyte reconsti-
tution after hematopoietic stem cell transplantation: functional
immaturity and slow recovery of memory CD27 B cells. Exp
Hematol. 2005;33:480-486.
43. American Academy of Pediatrics. Committee on Infectious
Diseases. Age for routine. Administration of the second dose of
measles-mumps-rubella vaccine. Pediatrics. 1998;101:129-133.
44. King SM, Saunders EF, Petric M, Gold R. Response to measles,
mumps and rubella vaccine in paediatric bonemarrow transplant
recipients. Bone Marrow Transplant. 1996;17:633-636.
45. BilukhaOO, RosensteinN. Prevention and control of meningo-
coccal disease. Recommendations of the Advisory Committee
on Immunization Practices (ACIP). MMWR. 2005;54:1-21.
46. Villa LL, Ault KA, Giuliano AR. Immunologic responses
following administration of a vaccine targeting human papillo-
mavirus Types 6, 11, 16, and 18. Vaccine. 2006;24:5571-5583.
47. Broder KR, CorteseMM, Iskander JK, et al. Preventing tetanus,
diphtheria, and pertussis among adolescents: use of tetanus tox-
oid, reduced diphtheria toxoid and acellular pertussis vaccines
recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR. 2006;55:1-34.
